Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Presented for research literature review only Guimares GNF (2026)
Both classes are highly effective in reducing cardiovascular events in patients with type 2 diabetes across the spectrum of CVD risk (notably, our prior work comparing across mediation classes suggests that SGLT2is may be even more favorable than GLP-1RAs for some outcomes, and are comparable on others), and we assume that taking both together is likely to be even more beneficial
Before choosing a provider, its essential to consider factors such as pricing, availability of compounded versions, and whether an in-person consultation is required
Exenatide ER Trade Names: Byetta (daily) Bydureon (weekly - extended release) Generic (Nov 2024) Drug Class: DPP-IV resistant Incretin (GLP-1 like) Mimetic Mechanism of Action: a synthetic analog of glucagon-like-polypeptide 1 (GLP-1) that is resistant to breakdown by DPP-IV
Mani and Natesan, 2018)
The SUSTAIN phase 3 program provided the pivotal efficacy and safety data supporting regulatory submissions
US$ 23.02
US$ 29.75
US$ 21.69
US$ 28.83
US$ 21.78
